公司资料

NovoCure Limited 股价、新闻与催化剂

股票代码:
NVCR
交易所:
NASDAQ
行业:
Biopharma
所在地:
Switzerland

股票表现

10.69 USD (-0.37%)

收盘价

最后更新: 2026年11月19日

1.83B USD

市值

股价为何变动

截至 2026年11月19日,NVCR 下跌 0.37%,收于 $10.69。当前新闻监测窗口内未发现新的同公司新闻。

公司概览

业务概览

NovoCure is a medical technology company focused on tumor treating fields, a non-invasive cancer treatment modality. Its business is centered on device-based oncology treatment rather than pharmaceuticals.

所在地与行业分类

NovoCure is headquartered in Switzerland and listed on NASDAQ. It sits in oncology medtech rather than biotechnology.

商业模式特征

The company depends on adoption of tumor treating fields, reimbursement, and clinical workflow integration. Investors watch usage growth, market expansion, and the breadth of oncology indications.

生物医药行业定位

NovoCure occupies a unique device-oncology niche within healthcare. It is not biotech, but it is highly relevant to cancer treatment innovation.

未来催化剂

  • NovoCure’s catalysts are TTFields adoption, reimbursement, and continued execution across tumor types. The company’s stock usually responds when utilization broadens and evidence strengthens.

近期新闻

新闻标题由机器翻译,详情为英文原文。

  1. 01
  2. 02
  3. 03

相似股票

商业成熟度、治疗领域或催化剂模式相近的同行公司。